LGND LIGAND PHARMACEUTICALS INC
FollowCOM NEW (common), issuer CIK 886163
Filings received so far for Q3 2026: 16 13F filers report a position in LGND shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.
Insider trades
| Owner | Date | Shares | Price | Filing |
|---|---|---|---|---|
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | -17 S | $307.74 | Form 4 |
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | -235 S | $307.1911 | Form 4 |
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | -404 S | $306.1834 | Form 4 |
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | -1,535 S | $304.5154 | Form 4 |
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | -1,976 S | $303.5444 | Form 4 |
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | -833 S | $302.5107 | Form 4 |
| Reardon Andrewofficer (CLO & Secretary) | 2026-10-02 | +340 M | $52.27 | Form 4 |
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
Events
Reardon Andrew disposed of 4,660 LGND shares on 2026-10-02, Form 4 filed 2026-10-06. 0001950232-26-000003
Accepted , ingested